P1109 Evaluation of patient-reported outcome measures (PROMs) of IBD patients who completed upadacitinib induction period
Bildiriler > Özet Bildiri
Yazarlar: T Kav Prof., N Unal, O K Bakkaloglu, T Kani, A Akpinar, P Akincioglu, T Eskazan, M Balamir, G Dagci, İ N Sendur, I Buyuktorun, S Barutcu, G Bengi, B Cavus, Nevin ORUÇ, O Atug, D Dincer, A I Hatemi, Y Z Erzin, A Tezel, M Toruner, A F Celik, F Akyuz
Journal of Crohn's and Colitis, , , Uluslararası, Özet Bildiri, Wos, cilt 19, ss i2037-i2037
DOI: 10.1093/ecco-jcc/jjae190.1283
Özet
Abstract Background Patient-reported outcome measures (PROMs) are used to assess the effectiveness of treatments received by patients in terms of clinical response in inflammatory bowel disease (IBD). We aimed to evaluate the perceived clinical response from the patient’s perspective using PRO2, IBD Control Questionnaire (ICQ) and Visual Analogue Scale (VAS) at the end of induction therapy in patients treated with upadacitinib. We also aimed to evaluate the correlation of PROMs with biochemical response. Methods We included IBD patients who underwent upadacitinib induction therapy from 01/07/2024 to 01/10/2024 in ten centers. ICQ and VAS assessments (Higher scores are better) were used in conjunction with CRP levels and PRO2 assessments (Lower scores are better) performed at baseline and at the end of induction treatment. Results A total of 75 patients who completed the induction phase were included, 52% were female and 50.7% were treated for Crohn’s disease (CD). Treatment was switched in 54.7% of patients due to uncontrolled chronic disease, in 42.7% for loss of response and in 2.7% for drug side effects. PRO2 mean scores were changed from 4.86 ± 3.06 to 1.67 ± 1.28 (p<0.05) and 18.61 + 10.42 to 7.36 + 5.10 (p<0.05) for ulcerative colitis (UC) and CD respectively. At the end of induction treatment, 47.2% of UC group and 66.7% in the CD group were classified as in clinical remission according to PRO2 scores. The rate of patients reporting side effects was 30.7%. Acne and skin rashes were reported more frequently (13.2 %). According to the visual analog scale, 80% of the patients reported improvement in their condition (p<0.05), and the mean VAS score and IBD control score were 71.9 and 13.7 (p<0.05) for patients in remission in the UC group and 70 and 14.7 (p<0.05) in the CD group compared to active patients. ICQ scores and VAS were negatively correlated with PRO2 scores and CRP levels (p<0.05 for both pairs). On the other hand both scores were not correlated with CDAI and mayo scores (p>0.05). Conclusion In this real-life cohort of patients treated with upadacitinib, 80% report a significant improvement in their condition. ICQ and VAS can be used to understand patients’ perspective on treatment efficacy. Conventional activity scores probably not helpful for early assessment of clinical activity compared to PROMs.